Industry updates from the field of stem cell research and regenerative medicine in November 2022
Abstract
Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non academic institutions in November 2022.
Tweetable abstract
Regenerative medicine industry news digest, November 2022
References
- 1. Cartherics. Peter MacCallum Cancer Centre and Cartherics announce collaboration to develop autologous CAR-T cell therapy for cutaneous T-cell lymphoma (2022). https://cartherics.com/news/peter-maccallum-cancer-centre-and-cartherics-announce-collaboration-to-develop-autologous-car-t-cell-therapy-for-cutaneous-t-cell-lymphoma/
- 2. Cynata Therapeutics. New trial using stem cells to stop kidney transplant rejection (2022). www.cynata.com/news/new-trial-using-stem-cells-to-stop-kidney-transplant-rejection
- 3. ElevateBio. ElevateBio and Affini-T Therapeutics announce partnership to advance Affini-T's T cell therapy programs targeting core oncogenic drivers (2022). www.elevate.bio/press-releases/elevatebio-and-affini-t-therapeutics-announce-partnership-to-advance-affini-ts-t-cell-therapy-programs-targeting-core-oncogenic-drivers
- 4. bit.bio. bit.bio expands its portfolio with three new human cell products for research and drug discovery in neurodegenerative and neurological diseases (2022). www.bit.bio/news/launch-mapt-gaba
- 5. FUJIFILM. Fujifilm invests $188 million in new cell culture media manufacturing facility (2022). www.fujifilm.com/us/en/news/FISI_North_Carolina
- 6. Biogennix. Biogennix's DirectCell advanced bone grafting system used in 1000th case (2022). https://biogennix.com/news/directcell-1000th-case/
- 7. ElevateBio. ElevateBio BaseCamp unveils its LentiPeak™ lentiviral vector platform (2022). www.elevate.bio/press-releases/elevatebio-basecamp-unveils-its-lentipeak-lentiviral-vector-platform
- 8. Namocell. Namocell highlighted in Nature Publication for efficient single cell cloning of human pluripotent stem cells (2022). www.namocell.com/namocell-highlighted-in-nature-publication/
- 9. Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail. Nat. Protoc. (2022). https://pubmed.ncbi.nlm.nih.gov/36261632/
- 10. Lineage Cell Therapeutics. Lineage announces launch of Phase IIA study by Genentech of RG6501 (OpRegen®) in patients with geographic atrophy secondary to age-related macular degeneration (2022). https://investor.lineagecell.com/node/22691/pdf
- 11. NCT05626114. A study to optimize subretinal surgical delivery and to evaluate safety and activity of opregen in participants with geographic atrophy secondary to age-related macular degeneration (2022). https://clinicaltrials.gov/ct2/show/NCT05626114
- 12. Edigene. EdiGene announces completion of last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion dependent β-thalassemia (2022). www.edigene.com/media/119.html
- 13. NCT04925206. A safety and efficacy study evaluating ET-01 in subjects with transfusion dependent β-thalassaemia (ET-01) (2022). https://clinicaltrials.gov/ct2/show/NCT04925206
- 14. Editas Medicine. Editas Medicine announces clinical data demonstrating proof of concept of EDIT-101 from Phase I/II BRILLIANCE trial (2022). https://ir.editasmedicine.com/node/11341/pdf
- 15. NCT03872479. Single ascending dose study in participants with LCA10 (2022). https://clinicaltrials.gov/ct2/show/NCT03872479
- 16. Priothera. Priothera – Positive mocravimod Phase IB clinical data published in transplantation and cellular therapy (2022). https://priothera.com/priothera-positive-mocravimod-phase-1b-clinical-data-published-in-transplantation-and-cellular-therapy/
- 17. Mocravimod, a selective sphingosine-1-phosphate receptor modulator, in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant. Cell Ther. 29(1), 41.e1–41.e9 (2022).
- 18. NCT05429632. Phase IIb placebo-controlled study of mocravimod as adjunctive and maintenance treatment in AML patients in allo-HSCT (MO-TRANS) (2022). https://clinicaltrials.gov/ct2/show/NCT05429632
- 19. Aleta Biotherapeutics. Aleta Biotherapeutics receives innovation passport designation for Biologic CAR T-cell therapy engager ALETA-001 (2022). http://www.aletabio.com/wp-content/uploads/2022/11/Aleta-Bio-Receives-IP-Designation-FINAL.pdf
- 20. AgeX Therapeutics. AgeX Therapeutics receives extension of time to attain compliance with stock exchange continued listing requirements (2022). https://investors.agexinc.com/news/news-details/2022/AgeX-Therapeutics-Receives-Extension-of-Time-to-Attain-Compliance-With-Stock-Exchange-Continued-Listing-Requirements/default.aspx
- 21. Hemanext. Hemanext announces close of series B equity funding round (2022). https://hemanext.com/hemanext-announces-close-of-series-b-equity-funding-round/
- 22. Novadip Biosciences. Novadip Biosciences raises additional EUR 40 million bringing total company funding to EUR 88 million (2022). https://novadip.com/press-releases/novadip-biosciences-raises-additional-eur-40-million-bringing-total-company-funding-to-eur-88-million/